Neo

@HullAndHeritage Mid

If as a young woman you do not look like this I’m sorry to inform you but it’s over for you

@MurrayHillGuy1 Because it’s not FDA approved?

Week 4 on Reta: – 16 lbs down – lifts are all up or holding steady – abs visible, insane vascularity – confidence through the roof – libido is high, having more sex than I have in years – focus and drive have never been more locked in why is everyone not on this?

@burkov @lufthansa Imbecile take

The average profit from one passenger a major airline like @lufthansa makes is about €8.15 (~$9.50).

@MurrayHillGuy1 You went to poor - try wealthy next

Spent a day in the suburbs today and I finally get it now… this is the endgame?? Train OUT was 45 min delayed just to get there (should’ve been my first warning) 11:00am: friend picks me up… immediately driving everywhere like we’re in a NASCAR qualifier. 11:25am: drive 20 min to the gym just to hit the most NPC workout of all time. Not a single hot chick. Few milfs, everyone in there built like they “used to play in high school” 1:30pm: drive 16 min for coffee/lunch… line of 12 people ordering the same vanilla oat milk whatever and a sandwich 2:00pm: overhear grown adults discussing mulch, lawn patterns, and “getting into smoking meats” like it’s a personality 3:30pm: neighborhood walk = same 6 houses copy pasted 50 times, every guy power walking with his hands behind his back 5:00pm: bout to hit a Costco run like it’s Disney World. samples = main event 6:00pm: going to dinner at a chain restaurant like Olive Garden where every couple looks like they’ve had the same conversation since 2014 8:00pm: town is pitch black, everyone inside, probably scrolling and watching Netflix hating their life. Back to NYC I go. people really escape the city just to live in a loop

@maxmarchione But the cardiovascular effects are brutal

Just about every >150 iq person I know uses nicotine. Nicotine is underrated and misunderstood

@TiehackCapital Skip the surgery seriously

PE-owned anesthesiologist putting me under in upcoming surgery. How cooked am I?

@RichardHanania They don’t get enough. They should get paid double

Average income of physicians US: $458,100 Canada: $194,700 Netherlands: $185,700 Sweden: $115,200 nber.org/papers/w34956

@rtnarch @drrichjlaw @ShiningScience Don’t respond to AI slop Bob - it’s bad form

Incorrect. Harvard did not pioneer this. Juan Carlos Izpisua Belmonte is the key pioneer for the first widely cited paper showing partial reprogramming had anti-aging effects in vivo. That 2016 Cell paper reported that short-term cyclic OSKM expression ameliorated age-associated hallmarks and extended lifespan in a mouse model of premature aging.[pubmed.ncbi.nlm.nih +1]

Scientists studying aging at Harvard and other research centers have been investigating a technique called partial epigenetic reprogramming. This method attempts to reset some of the biological markers associated with aging inside cells without completely turning them back into stem cells. The research is based on “Yamanaka factors,” a group of genes that can influence how cells express their genetic instructions. In animal experiments, activating specific combinations of these factors helped restore certain cellular functions and improved tissue repair in damaged areas. Much of the attention around this research comes from experiments in mice where scientists observed changes in epigenetic markers associated with aging. These markers are part of what researchers call the “epigenetic clock,” which tracks biological aging through chemical changes on DNA. However, translating results from animals to humans is complex and takes years of testing. Early clinical trials that receive FDA clearance are primarily designed to evaluate safety rather than confirm that the treatment reverses aging. If future studies prove successful, this field could reshape regenerative medicine by focusing on repairing or resetting aging cells. For now, scientists consider it an exciting early step toward understanding how aging works at the cellular level.

@MaryBowdenMD Skill issue

1367 US medical students did not get a US residency spot. 6733 international, non-US medical students got a US residency spot.

@MarketPalmer_ Divorce

Recently learned that 25% of 60-year old doctors have a net worth below $1 million. How…?

@BiotechAnalysst For the promotion

WTF would someone go from $bbio to $sgmo ???????

@AKaBooM34 @celinehalioua @AlexJColville @US_FDA If you think a random “drug” will increase lifespan in dogs you must be imbecile, shill or demented you pick

@NEObioMATRIX @celinehalioua @AlexJColville @US_FDA To you apparently. Not to me - veterinary professional who spent time in human drugs/drug claims support/clinicals. Help me understand why it's not a good look. Honest question. Loyal is working to increase Healthspan, an area that's being worked for humans as well.

we have taken over the SF mint

@Biohazard3737 These are rookie numbers

@Biohazard3737 So let’s approve one more of those? Why don’t withdraw the ones in the market first?

@negligible_cap Is this great investor here with us?

It’s crazy that both Bill Ackman and Michael Burry got super bullish on $FNMA and $FMCC and both wrote long form posts and pitches on the two GSEs Fannie Mae and Freddie Mac are each down around 60% in the last 6 months Burry and Ackman have been getting creamed along with everyone who followed them into the trade. Even great investors get it wrong or get the timing wrong at a minimum

@matthewherper They don’t care

This morning's BioNTech news strikes me as very odd. Certainly, founder Ugur Sahin and Ozlem Tureci shouldn't feel compelled to run the company forever, and they may not be the right people to manage both the continued decline of Covid-19 vaccine sales and the launch of new cancer drugs. And given the disastrous quarterly numbers the company posted -- a per share loss for the quarter that was triple what analysts expected, revenue guidance for the year about half a billion Euro below analyst forecasts -- there is a good argument someone else needs to be playing the game of managing expectations here. But they are also key to the identity of the company, and announcing their departure without a successor in hand feels to me like a failure of leadership that only adds uncertainty at a time when it is already high. The stock is down 18%. $BNTX Our story here, by @DrewQJoseph. statnews.com/2026/03/10/bio… via @statnews

@business Is this the onion?

A new demand from the FDA in a clinical trial for a cutting-edge gene therapy from UniQure is raising ethical questions bloomberg.com/news/articles/…

@DrMakaryFDA @JessieChimni You can just live stream from your desk boss! Will look better and more authoritative. Try it next time! Good job

FDA is moving with unprecedented agility. Today we approved a multiple myeloma drug just 55 days after the application was filed. And last week’s approval (a major leap forward) was approved in 44 days. If a trial result shows immediate promise for many Americans, why wait?

@AlexBerenson @Sensible__Med @US_FDA They aspire to become sarepta! Making billions selling dangerous placebo

No, @US_FDA is not stopping a silver bullet for Huntington's disease! Huntington's is awful. But the proposed treatment made patients WORSE during the 12-month blinded control period compared to people who didn't get it. And several patients suffered severe illnesses from it...

@celinehalioua Where is the clinical data for the efficacy claim? Show us the data!

our dog longevity drug LOY-002 has earned FDA safety approval we now have 2 of 3 major sections of our New Animal Drug Application complete (!) if (when) we earn FDA manufacturing approval, Loyal will launch the *first FDA-approved lifespan extension drug*